AZN - Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry | Benzinga
In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing AstraZeneca (NASDAQ:AZN) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
AstraZeneca Background
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | |||||||
| 31.35 | |||||||
| 5.13 | |||||||
| 4.34 | |||||||
| 4.97% | |||||||
| $3.79 | |||||||
| $9.46 | |||||||
| 5.99% | |||||||
| Eli Lilly and Co | |||||||
| 78.03 | |||||||
| 48.07 | |||||||
| 17.16 | |||||||
| 15.85% | |||||||
| $2.58 | |||||||
| $6.5 | |||||||
| 28.12% | |||||||
| Novo Nordisk A/S | |||||||
| 44.37 | |||||||
| 32.63 | |||||||
| 14.82 | |||||||
| 22.81% | |||||||
| $26.71 | |||||||
| $46.44 | |||||||
| 31.59% | |||||||
| Novartis AG | |||||||
| 23.90 | |||||||
| 4.97 | |||||||
| 3.60 | |||||||
| 3.91% | |||||||
| $4.88 | |||||||
| $8.97 | |||||||
| 12.14% | |||||||
| Pfizer Inc | |||||||
| 8.01 | |||||||
| 1.72 | |||||||
| 2.21 | |||||||
| 2.33% | |||||||
| $4.35 | |||||||
| $9.5 | |||||||
| -54.1% | |||||||
| Sanofi SA | |||||||
| 11.92 | |||||||
| 1.41 | |||||||
| 2.21 | |||||||
| 1.98% | |||||||
| $2.53 | |||||||
| $7.41 | |||||||
| -0.56% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 13.57 | |||||||
| 3.25 | |||||||
| 2.39 | |||||||
| 6.5% | |||||||
| $4.57 | |||||||
| $8.35 | |||||||
| -5.56% | |||||||
| Zoetis Inc | |||||||
| 32.85 | |||||||
| 15.53 | |||||||
| 8.84 | |||||||
| 14.72% | |||||||
| $1.05 | |||||||
| $1.57 | |||||||
| 6.24% | |||||||
| GSK PLC | |||||||
| 11.27 | |||||||
| 4.61 | |||||||
| 2 | |||||||
| 13.25% | |||||||
| $2.62 | |||||||
| $5.25 | |||||||
| 3.59% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 33.32 | |||||||
| 0.90 | |||||||
| 1.53 | |||||||
| -0.69% | |||||||
| $190.78 | |||||||
| $699.51 | |||||||
| 4.07% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 19.07 | |||||||
| 3.68 | |||||||
| 3.45 | |||||||
| 5.89% | |||||||
| $22.4 | |||||||
| $39.55 | |||||||
| 29.2% | |||||||
| Viatris Inc | |||||||
| 5.73 | |||||||
| 0.50 | |||||||
| 0.68 | |||||||
| 1.26% | |||||||
| $1.16 | |||||||
| $1.61 | |||||||
| -4.81% | |||||||
| Average | |||||||
| 25.64 | |||||||
| 10.66 | |||||||
| 5.35 | |||||||
| 7.98% | |||||||
| $23.97 | |||||||
| $75.88 | |||||||
| 4.54% |